Navigation Links
Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42
Date:8/12/2008

basic and diluted 62.5 62.5 62.5 62.5

* Hillenbrand, Inc.'s first dividend as a stand-alone public company was

paid June 30, 2008. As a result, there are no dividends reported for the

first two quarters of fiscal 2008 or the entire prior year.

Hillenbrand, Inc.

Consolidated Balance Sheets (Unaudited)

(Dollars in millions)

June 30 September 30

2008 2007

ASSETS

Current Assets

Cash and cash equivalents $33.0 $11.9

Trade receivables, net 85.6 90.9

Inventories 50.3 47.5

Deferred income taxes 18.8 16.0

Prepaid income taxes 0.6 0.3

Other current assets 8.5 3.6

Total current assets 196.8 170.2

Property, net 91.2 88.9

Intangible assets, net 20.7 23.0

Auction rate securities 52.7 -

Investments 153.4 -

Prepaid pension costs - 1.6

Deferred income taxes 10.9 16.2

Due from Hill-Rom Holdings, Inc. 9.1 -

Other assets 31.6 16.7

Total Assets $566.4 $316.6

LIABILITIES

Current Liabilities

Revolving credit facility $110.0 $-

Trade
'/>"/>

SOURCE Hillenbrand, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company
2. Hillenbrand, Inc. Names Joe A. Raver President and Chief Operating Officer of Batesville Casket Company
3. Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ation and treatment clinics to resume Monday, Nov....ovember 25, 2009 -- Centegra Health System is cont...ne shots at four Centegra Primary Care (CPC) vacci...as arrived. The clinics are at CPC sites in Huntle... open as follows: ,   From 4:30 to 7:3...
(Date:11/25/2009)...ological symptoms, study finds , , WEDN...de effects are among the potential problems faced ...re treated with cisplatin-based chemotherapy, a ne...orwegian men treated for unilateral testicular can...w-up survey conducted from 1998 to 2002. , The ...
(Date:11/25/2009)...re/-- MISSIONSkincare ®isproudtosupportGNC,se...NC,sannualSt.Jude ThanksandGiving campaign,$1fromt...ER-C(TM)LipBalm willbedonatedtoSt.Jude.Additionall...onationatcheckoutatoneoftheir5,000+retaillocations...Judeduringtheir2009 ThanksandGiving campaign. ,...
(Date:11/25/2009)...nforthe4thStraightYear ,, WASHINGTON,Nov.25/P...Georgia(LCA-GA)issuedthe 4thAnnualReportCardonLung...eagainstthislethaldiseaseinthestateofGeorgia.LCA-G...alorganizationdedicatedexclusivelytopatientsupport...r. ,, (Logo: http://www.newscom.com/cgi-bin/prn...
(Date:11/25/2009)...al cancer also can reverse a rare stomach disorder...he disease, researchers at Vanderbilt University M...se causes thickening of the stomach lining, severe...nemia and swelling in the feet and ankles due to p...stric cancer. Previously, the only effective treat...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...an research groups are undertaking pioneering stud...ing to patients receiving new drug treatments as e...fessor Shaun Jackson from The Australian Centre fo...tigating the impact of the bone marrow microenviro...
...arch 9, 2009 An easily implementable technique to...ed through angioplasty and stent insertion has bee...nsky of the Hebrew University of Jerusalem. , A... to part of the beating heart, usually due to plaq...
...n California Practice to Join SpectraScience Netwo...ystem , , SAN DIEGO, March 9 SpectraScience, Inc...dical device company, today announced that it has ... founder of Women,s Integrative Health, stated, "W...
...March 9 CEL-SCI Corporation (NYSE Alternext US: C...clusive licensing agreement with Byron Biopharma (...exclusive license to market and distribute the Com...th Teva Pharmaceuticals and Orient Europharma. , ...
... Journal of Radiation Oncology*Biology*Physics Stu...stem Provides Enhanced Image Information for Plann...REAL, March 4 Researchers report in the February ... enhanced image information to enable radiation on...
...., March 9 VirtualHealth Technologies, Inc. (OTC ...ve immediately it,s subsidiary Envoii Healthcare, ...o better reflect it,s focus on eHealth Security pr...t on growing our opportunities in this evolving cl...
Other Medicine News:Health News:World first treatment for leukemia being developed in Australia 2Health News: Hebrew University scientist develop technique for eliminating reblockage of arteries 2Health News:Women's Integrative Health Encinitas OB/GYN Selects LUMA Cervical Imaging System 2Health News:Women's Integrative Health Encinitas OB/GYN Selects LUMA Cervical Imaging System 3Health News:CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa 2Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 2Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 3Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 4Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 2Health News:Envoii Healthcare, LLC is now Secure eHealth, LLC 3
(Date:11/25/2009)....,Nov.25/PRNewswire/--CempraPharmaceuticalsInc.tod...iefexecutiveofficer,willpresentatthePiperJaffray21...1,2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fer...gantibioticclinicalprogramsforthetreatmentofdrug-r...Pharmaceuticals ,, Foundedin2006,CempraPharmac...
(Date:11/25/2009)...alif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,anno...y,sPROTECT-1(theProspectiveRandomizedOralTherapyEv...X282-B)inpatientswithmoderate-to-severeCrohn,sdise...yandtolerabilityprofile.Thestudydemonstratedeviden...yasdefinedasa70-pointdecreaseintheCrohn,sDiseaseAc...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Vermillion,Inc.(VRM...nofReorganizationandDisclosureStatementtoday,Novem...eDistrictofDelaware.Ahearingtoconsiderapprovalofth...r8,2009,withthehearingontheconfirmationofthePlansc...ompanytopayallclaimsinfull.ThePlanisexpected,ifapp...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 1Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 2Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 1Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 2Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 4Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 5Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 6Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 7Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 8Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 1Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 2Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 3
... increase in advanced non-small cell, lung cancer ...clitaxel and cisplat...include reductions in chemotherapy-indu...OKYO, March 18 BioNumerik,Pharmaceuticals, Inc. (...ASKA") today announced the results of a Phase III ...
... 2b in Second Quarter of 2008 - - Conferen... DIEGO, March 17 Ardea Biosciences, Inc.,(Nasdaq:...lts from its,ongoing Phase 2a proof-of-concept stu...oside reverse transcriptase inhibitor (NNRTI), in,... Preliminary results from the first two of three ...
Other Medicine Technology:BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 2BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 3BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 4BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 5Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
UPJ Occlusion Balloon Catheter
Omega NV Balloon Ureteral Dilator Sets
AquaGuide Ureteral Access Sheath
Flexible Ureteroscopy Sheath Set
Medicine Products: